Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Bladder Cancer

  Free Subscription


16.04.2018

1 Actas Urol Esp
1 Anticancer Res
1 Biomed Pharmacother
2 BJU Int
1 Environ Sci Pollut Res Int
1 Eur J Cancer
2 Eur Urol
1 Int J Mol Sci
2 J Urol
1 Medicine (Baltimore)
1 Nat Rev Urol
1 Niger J Surg
1 Oncoimmunology
13 Transl Androl Urol
6 Urol Clin North Am
1 Urol Oncol
3 Urologe A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Actas Urol Esp

  1. MARCH-VILLALBA JA, Panach-Navarrete J, Herrero-Cervera MJ, Alino-Pellicer S, et al
    hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test(R).
    Actas Urol Esp. 2018 Apr 6. pii: S0210-4806(18)30050.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. MAKINO T, Izumi K, Natsagdorj A, Iwamoto H, et al
    Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
    Anticancer Res. 2018;38:2241-2245.
    PubMed     Text format     Abstract available


    Biomed Pharmacother

  3. WANG JS, Liu QH, Cheng XH, Zhang WY, et al
    The long noncoding RNA ZFAS1 facilitates bladder cancer tumorigenesis by sponging miR-329.
    Biomed Pharmacother. 2018;103:174-181.
    PubMed     Text format     Abstract available


    BJU Int

  4. FRANSEN VAN DE PUTTE EE, Bosschieter J, van der Kwast TH, Bertz S, et al
    The WHO 1973 classification system for grade is an Important prognosticator in T1 non-muscle-invasive bladder cancer.
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238.
    PubMed     Text format     Abstract available

  5. CHA EK, Sfakianos JP, Sukhu R, Yee AM, et al
    Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14242.
    PubMed     Text format     Abstract available


    Environ Sci Pollut Res Int

  6. HAMEED DA, Yassa HA, Agban MN, Hanna RT, et al
    Genetic aberrations of the K-ras proto-oncogene and in bladder cancer in relation to pesticide exposure.
    Environ Sci Pollut Res Int. 2018 Apr 12. pii: 10.1007/s11356-018-1840.
    PubMed     Text format     Abstract available


    Eur J Cancer

  7. ANDREASSEN BK, Grimsrud TK, Haug ES
    Bladder cancer survival: Women better off in the long run.
    Eur J Cancer. 2018;95:52-58.
    PubMed     Text format     Abstract available


    Eur Urol

  8. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    PubMed     Text format    

  9. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    PubMed     Text format    


    Int J Mol Sci

  10. GOU L, Liu M, Xia J, Wan Q, et al
    BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    J Urol

  11. CHANG SS
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.
    PubMed     Text format    

  12. CHANG SS
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.
    PubMed     Text format    


    Medicine (Baltimore)

  13. PU X, Zhu L, Fu Y, Fan Z, et al
    Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer.
    Medicine (Baltimore). 2018;97:e0353.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  14. GORIKI A, Seiler R, Wyatt AW, Contreras-Sanz A, et al
    Unravelling disparate roles of NOTCH in bladder cancer.
    Nat Rev Urol. 2018 Apr 11. pii: 10.1038/s41585-018-0005.
    PubMed     Text format     Abstract available


    Niger J Surg

  15. IKUEROWO SO, Ojewuyi OO, Bioku MJ, Abolarinwa AA, et al
    Outcome of Mainz II Pouch Urinary Diversion after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer: Our Experience.
    Niger J Surg. 2018;24:12-15.
    PubMed     Text format     Abstract available


    Oncoimmunology

  16. TSURUTA M, Ueda S, Yew PY, Fukuda I, et al
    Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4(+) T cells expressing converged T-cell receptor genes in vitro.
    Oncoimmunology. 2018;7:e1415687.
    PubMed     Text format     Abstract available


    Transl Androl Urol

  17. LIPPI G, Del Rio D
    Nutritional habits and bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  18. CRETA M, Longo N, Imbimbo C, Imperatore V, et al
    Health-related quality of life in bladder cancer patients undergoing radical cystectomy and urinary stoma: still many gaps.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  19. DOBBS RW, Abern MR
    A novel bladder cancer urinary biomarker: can it go where no marker has gone before?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  20. MORALES-BARRERA R, Gonzalez M, Suarez C, Carles J, et al
    Detection of circulating tumor DNA for advanced bladder cancer: where are we going?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  21. TAN Z, D'Costa NM, Raven PA, Chavez-Munoz C, et al
    Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  22. KIM AH, Kim SP
    Surviving travel or travelling to survive: the association of travel distance with survival in muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  23. TAN WS, Tan WP
    Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  24. HAQUE W, Butler EB, Teh BS
    Clinical benefit to regionalization of care for muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  25. FONTEYNE V, Rammant E, Decaestecker K
    Selecting candidates for early discharge after radical cystectomy for bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  26. SORIA F, Gontero P
    How to assess and improve health-related quality of life in bladder cancer patients.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  27. SYLVESTER R
    A single immediate instillation of chemotherapy for non-muscle invasive bladder cancer: in all patients?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  28. OOSTERLINCK W, Decaestecker K
    Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  29. BANERJEE S, Banerjee S
    Robot-assisted laparoscopic implantation of brachytherapy catheters in bladder cancer recent interests and prospective.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    


    Urol Clin North Am

  30. TEO MY, Rosenberg JE
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:287-295.
    PubMed     Text format     Abstract available

  31. ACHKAR T, Parikh RA
    Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:257-266.
    PubMed     Text format     Abstract available

  32. ZAINFELD D, Shah A, Daneshmand S
    Enhanced Recovery After Surgery Pathways: Role and Outcomes in the Management of Muscle Invasive Bladder Cancer.
    Urol Clin North Am. 2018;45:229-239.
    PubMed     Text format     Abstract available

  33. SATHIANATHEN NJ, Risk MC, Konety BR
    Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.
    Urol Clin North Am. 2018;45:215-228.
    PubMed     Text format     Abstract available

  34. TABAYOYONG W, Li R, Gao J, Kamat A, et al
    Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:155-167.
    PubMed     Text format     Abstract available

  35. MOSSANEN M, Chang SL, Kimm S, Sonpavde GP, et al
    Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.
    Urol Clin North Am. 2018;45:143-154.
    PubMed     Text format     Abstract available


    Urol Oncol

  36. KLAPHEKE A, Yap SA, Pan K, Cress RD, et al
    Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
    Urol Oncol. 2018 Apr 5. pii: S1078-1439(18)30084.
    PubMed     Text format     Abstract available


    Urologe A

  37. HORN T, Krege S, Retz M
    [Advanced bladder cancer : From chemo- to immunotherapy].
    Urologe A. 2018 Apr 10. pii: 10.1007/s00120-018-0626.
    PubMed     Text format     Abstract available

  38. TSELIS N, Prott FJ, Ott O, Weiss C, et al
    [Radiochemotherapy for invasive bladder cancer : An update].
    Urologe A. 2018 Apr 12. pii: 10.1007/s00120-018-0628.
    PubMed     Text format     Abstract available

  39. STRUCK JP, Karl A, Schwentner C, Herrmann TRW, et al
    [En bloc resection and vaporization techniques for the treatment of bladder cancer].
    Urologe A. 2018 Apr 12. pii: 10.1007/s00120-018-0625.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: